



Date: 03.08.2024

TO,
The Dy. Gen Manager
Corporate Relationship Dept.
BSE Limited
P. J. Tower, Dalal Street,
Mumbai- 400 001

Scrip Code: 524632

Dear Sir,

Sub: Intimation of meeting of the Board of Directors pursuant to Regulation 29 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015

Pursuant to Regulation 29 read with other applicable Regulation of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Monday, 12th August 2024, at the Registered Office of the Company inter alia to consider and approve the following: -

1. To Consider, Adopt and Approve Unaudited financial result for the quarter ended on 30th June, 2024.
2. To Any other business with the permission of Chairman.

In terms of the Company's Code of Conduct for Prevention of Insider Trading, the "Trading Window" for dealing in securities of the Company has been closed from 28th June, 2024 till the end of 48 hours after the declaration of the Unaudited Financial Results of the Company for the quarter ended 30th June 2024.

Please take the same on record.

Thanking you,

Yours faithfully

For Shukra Pharmaceuticals Limited

Arpita Kabra
Company Secretary and Compliance Officer
Membership Number: A50258



CIN : L24231GJ1993PLC019079